Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the β cell.

Kuliawat R, Klein L, Gong Z, Nicoletta-Gentile M, Nemkal A, Cui L, Bastie C, Su K, Huffman D, Surana M, Barzilai N, Fleischer N, Muzumdar R

FASEB journal : official publication of the Federation of American Societies for Experimental Biology30 Aug 2013Cited by 69 (Europe PMC)

PMID23995290PMCIDPMC3834779DOI10.1096/fj.13-231092PepBankPUB-23995290

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

01AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome
In Sprague-Dawley rats, the humanin analog HNGF6A raised the glucose infusion rate needed during hyperglycemic clamps versus saline.
In plain wordsIn rats, a humanin analog raised the glucose infusion rate needed during clamps, compared with saline.
Peptide
Humanin
Outcome
IncreaseGlucose infusion rate during hyperglycemic clamp
Study
ratn: not reported in source
Sprague-Dawley rats, hyperglycemic clamp
Comparator
Saline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Sprague-Dawley rats (3 mo old) that received HNGF6A required a significantly higher glucose infusion rate and demonstrated higher insulin levels during hyperglycemic clamps compared to saline controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine β cell line (βTC3) in vitro.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Report a problemFND-2399529001
02AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome
In Sprague-Dawley rats, the humanin analog HNGF6A gave higher insulin levels during hyperglycemic clamps than saline.
In plain wordsIn rats, a humanin analog gave higher insulin levels during clamps than saline did.
Peptide
Humanin
Outcome
IncreaseInsulin level during hyperglycemic clamp
Study
ratn: not reported in source
Sprague-Dawley rats, hyperglycemic clamp
Comparator
Saline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Sprague-Dawley rats (3 mo old) that received HNGF6A required a significantly higher glucose infusion rate and demonstrated higher insulin levels during hyperglycemic clamps compared to saline controls.
1 context sentence(design, population, supporting numbers)
Summary · context
Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine β cell line (βTC3) in vitro.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Report a problemFND-2399529002
03LabNot a test of Humanin aloneEx vivo tissueEfficacy outcome
In isolated islets from normal mice, HNGF6A increased glucose-stimulated insulin secretion versus scrambled peptide.
In plain wordsIn islets from healthy mice, a humanin analog raised glucose-triggered insulin release more than a scrambled peptide.
Peptide
Humanin
Outcome
IncreaseGlucose-stimulated insulin secretion in islets from normal mice
Study
mousen: not reported in source
Isolated islets from normal mice
Comparator
Scrambled peptide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In vitro, compared to scrambled peptide controls, HNGF6A increased GSIS in isolated islets from both normal and diabetic mice as well as in βTC3 cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine β cell line (βTC3) in vitro.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Report a problemFND-2399529003
04LabNot a test of Humanin aloneEx vivo tissueEfficacy outcome
In isolated islets from diabetic mice, HNGF6A increased glucose-stimulated insulin secretion versus scrambled peptide.
In plain wordsIn islets from diabetic mice, a humanin analog raised glucose-triggered insulin release more than a scrambled peptide.
Peptide
Humanin
Outcome
IncreaseGlucose-stimulated insulin secretion in islets from diabetic mice
Study
mousen: not reported in source
Isolated islets from diabetic mice
Comparator
Scrambled peptide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In vitro, compared to scrambled peptide controls, HNGF6A increased GSIS in isolated islets from both normal and diabetic mice as well as in βTC3 cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine β cell line (βTC3) in vitro.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Report a problemFND-2399529004
05LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome
In βTC3 cells, HNGF6A increased glucose-stimulated insulin secretion versus scrambled peptide.
In plain wordsIn cells from a mouse beta cell line, a humanin analog raised glucose-triggered insulin release more than a scrambled peptide.
Peptide
Humanin
Outcome
IncreaseGlucose-stimulated insulin secretion in βTC3 cells
Study
mousen: not reported in source
Murine beta cell line (βTC3)
Comparator
Scrambled peptide
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In vitro, compared to scrambled peptide controls, HNGF6A increased GSIS in isolated islets from both normal and diabetic mice as well as in βTC3 cells.
1 context sentence(design, population, supporting numbers)
Summary · context
Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine β cell line (βTC3) in vitro.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Report a problemFND-2399529005
06LabNot a test of Humanin aloneIn vitro (cells)Mechanism
In islets and βTC3 cells, the effect of HNGF6A on glucose-stimulated insulin secretion was dose dependent.
In plain wordsIn lab tests on islets and cells, the humanin analog raised insulin release more at higher doses.
Peptide
Humanin
Outcome
IncreaseDose dependence of HNGF6A effect on insulin secretion
Study
mousen: not reported in source
Isolated islets and βTC3 cells
Outcome group
Receptor activity and mechanism · Metabolic and weight
Source sentences
Summary
Effects of HNGF6A on GSIS were dose dependent, K-ATP channel independent, and associated with enhanced glucose metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine β cell line (βTC3) in vitro.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Report a problemFND-2399529006
07LabNot a test of Humanin aloneIn vitro (cells)Mechanism
In islets and βTC3 cells, the effect of HNGF6A on glucose-stimulated insulin secretion was K-ATP channel independent.
In plain wordsIn lab tests on islets and cells, the humanin analog's effect on insulin release did not depend on K-ATP channels.
Peptide
Humanin
Outcome
No significant changeK-ATP channel dependence of HNGF6A effect
Study
mousen: not reported in source
Isolated islets and βTC3 cells
Outcome group
Receptor activity and mechanism · Metabolic and weight
Source sentences
Summary
Effects of HNGF6A on GSIS were dose dependent, K-ATP channel independent, and associated with enhanced glucose metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine β cell line (βTC3) in vitro.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Report a problemFND-2399529007
08LabNot a test of Humanin aloneIn vitro (cells)Mechanism
In islets and βTC3 cells, the effect of HNGF6A on insulin secretion was associated with enhanced glucose metabolism.
In plain wordsIn lab tests on islets and cells, the humanin analog's effect on insulin release went with higher glucose metabolism.
Peptide
Humanin
Outcome
IncreaseGlucose metabolism with HNGF6A
Study
mousen: not reported in source
Isolated islets and βTC3 cells
Outcome group
Receptor activity and mechanism · Metabolic and weight
Source sentences
Summary
Effects of HNGF6A on GSIS were dose dependent, K-ATP channel independent, and associated with enhanced glucose metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
Effects of a potent HN analog, HNGF6A, on glucose-stimulated insulin secretion (GSIS) were assessed in vivo and in isolated pancreatic islets and cultured murine β cell line (βTC3) in vitro.
In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.
Report a problemFND-2399529008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.